APR Applied Pharma Research

APR Applied Pharma Research is a mission-driven Swiss pharma company focused on improving the lives of patients with rare diseases through innovative, patent-protected products. The company has successfully built a portfolio of marketed products, including PKU GOLIKE® and Nexodyn®, and maintains a promising clinical pipeline. Its strategy integrates direct commercialization in key European markets with a global partner network and a complementary CDMO services division, creating a diversified and resilient business.

APR's innovation is based on proprietary drug delivery platforms including Tehclo™ (topical acid-oxidizing solutions), Physiomimic™ (metabolic/nutritional), ODF (orally disintegrating films), and Dynamic Buffering (immediate release) technologies.

APR competes in niche segments: in rare diseases against other specialty pharma and medical nutrition companies, and as a CDMO against other formulation-specialty service providers. Its strategy of using drug delivery to differentiate established molecules allows it to address unmet needs without always competing directly with novel biologic therapies.